SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

26 May 2023 Evaluate
The sales for the March 2023 quarter moved down to Rs. 3888.14 millions as compared to Rs. 4762.33 millions during the year-ago period.The Company to register a -53.99%  fall in the net profit for the quarter ended March 2023.A decline of 376.97 millions was observed in the OP in the quarter ended March 2023 from 496.70 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 3888.14 4762.33 -18.36 15246.09 16682.56 -8.61 15246.09 16682.56 -8.61
Other Income 179.25 5.20 3347.12 422.39 112.93 274.03 422.39 112.93 274.03
PBIDT 376.97 496.70 -24.11 979.02 1701.31 -42.45 979.02 1701.31 -42.45
Interest 196.58 174.31 12.78 794.77 788.10 0.85 794.77 788.10 0.85
PBDT 180.39 322.39 -44.05 184.25 913.21 -79.82 184.25 913.21 -79.82
Depreciation 148.49 142.57 4.15 591.19 569.68 3.78 591.19 569.68 3.78
PBT 31.90 179.82 -82.26 -406.94 343.53 -218.46 -406.94 343.53 -218.46
TAX -21.74 63.24 -134.38 -182.37 90.34 -301.87 -182.37 90.34 -301.87
Deferred Tax -21.74 63.24 -134.38 -182.37 90.34 -301.87 -182.37 90.34 -301.87
PAT 53.64 116.58 -53.99 -224.57 253.19 -188.70 -224.57 253.19 -188.70
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 8.43 9.07 -7.04 5.60 8.84 -36.61 5.60 8.84 -36.61

Nectar Lifesciences Share Price

12.17 -0.17 (-1.38%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×